Discovery and early clinical evaluation of BMS-605339, a potent and orally efficacious tripeptidic acylsulfonamide ns3 protease inhibitor for the treatment of hepatitis C virus infection

Journal of Medicinal Chemistry

Volumn 57, Issue 5, 2014, Pages 1708-1729

  Scola, Paul M ^a   Wang, Alan Xiangdong ^a   Good, Andrew C ^a   Sun, Li Qiang ^a   Combrink, Keith D ^a   Campbell, Jeffrey A ^a   Chen, Jie ^a   Tu, Yong ^a   Sin, Ny ^a   Venables, Brian L ^a   Sit, Sing Yuen ^a   Chen, Yan ^a   Cocuzza, Anthony ^a   Bilder, Donna M ^a   D'Andrea, Stanley ^a   Zheng, Barbara ^a   Hewawasam, Piyasena ^a   Ding, Min ^a   Thuring, Jan ^a   Li, Jianqing ^a   Hernandez, Dennis ^a   Yu, Fei ^a   Falk, Paul ^a   Zhai, Guangzhi ^a   Sheaffer, Amy K ^a   Chen, Chaoqun ^a   Lee, Min S ^a   Barry, Diana ^a   Knipe, Jay O ^a   Li, Wenying ^a   Han, Yong Hae ^a   Jenkins, Susan ^a   Gesenberg, Christoph ^a   Gao, Qi ^a   Sinz, Michael W ^a   Santone, Kenneth S ^a   Zvyaga, Tatyana ^a   Rajamani, Ramkumar ^a   Klei, Herbert E ^a   Colonno, Richard J ^a   Grasela, Dennis M ^a   Hughes, Eric ^a   Chien, Caly ^a   Adams, Stephen ^a   Levesque, Paul C ^a   Li, Danshi ^a   Zhu, Jialong ^a   Meanwell, Nicholas A ^a   McPhee, Fiona ^a   more..

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 CHLORO 6 METHOXYISOQUINOLINE; 2 [[[1 [[(CYCLOPROPYLSULFONYL)AMINO]CARBONYL] 2 ETHENYLCYCLOPROPYL]AMINO]CARBONYL] 4 [(6 METHOXY 1 ISOQUINOLINYL)OXY] 1 PYRROLIDINE HYDROCHLORIDE; 6 METHOXY 2H ISOQUINOLIN 1 ONE; ANTIVIRUS AGENT; BMS 605339; ISOQUINOLINE; ISOQUINOLINE DERIVATIVE; N BOC 3 (6 METHOXY 1 OXO ISOQUINOLINE)LEVO PROLINE; NONSTRUCTURAL PROTEIN 3; PROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DOG; DRUG POTENCY; DRUG STRUCTURE; HAPLORHINI; HEPATITIS C; HEPATITIS C VIRUS; MALE; NONHUMAN; RAT;

ANIMALS; ANTIVIRAL AGENTS; CRYSTALLOGRAPHY, X-RAY; DOGS; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; HEPATITIS C; HUMANS; ISOQUINOLINES; MODELS, MOLECULAR; PROTEASE INHIBITORS; SULFONAMIDES; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84896258592     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm401840s     Document Type: Article

References (83)

1. Kim, W. R. Global epidemiology and burden of hepatitis C Microbes Infect. 2002, 4, 1219-1225
2. WHO Hepatitis C global prevalence (update) Wkly. Epidemiol. Rec. 1999, 74, 425-427
3. Hanafiah, K. M.; Groeger, J.; Flaxman, A. D.; Wiersma, S. T. Global epidemiology of hepatits C virus infection: new estimates of age-specific antibody to HCV seroprevalence Hepatology 2013, 57, 1333-1342
4. Hajarazadeh, B.; Grebely, J.; Dore, G. J. Epidemiology and natural history of HCV infection Nat. Rev. Gastroenterol. Hepatol. 2013, 10, 553-562
5. Liang, T. J.; Heller, T. Pathogenesis of hepatitis C-associated hepatocellular carcinoma Gastroenterology 2004, 127, S62-S71
6. Pawlotsky, J.-M. Pathophysiology of hepatitis C virus infection and related liver disease Trends Microbiol. 2004, 12, 96-102
7. Zein, N. N. Clinical significance of hepatitis C virus genotypes Clin. Microbiol. Rev. 2000, 13, 223-235
8. Nakano, T.; Lau, G. M. G.; Lau, G. M. L.; Sugiyama, M.; Mizokami, M. An updated analysis of hepatitis C virus genotypes and subtypes based on the complete coding region Liver Int. 2012, 32, 339-345
9. Hoofnagle, J. H.; Seeff, L. B. Peginterferon and ribavirin for chronic hepatitis C N. Engl. J. Med. 2006, 355, 2444-2451
10. Pearlman, B. L. Extended-therapy duration for chronic hepatitis C genotype 1: the long and the short of it World J. Gastroenterol. 2008, 14, 3621-3627
11. Hadziyannis, S. J.; Sette, H.; Morgan, T. R.; Balan, V.; Diago, M.; Marcellin, P.; Ramadori, G.; Bodenheimer, H., Jr.; Bernstein, D.; Rizzetto, M.; Zeuzem, S.; Pockros, P. J.; Lin, A.; Ackrill, A. M.; PEGASYS International Study Group. Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose Ann. Intern. Med. 2004, 140, 346-355
12. De Francesco, R.; Migliaccio, G. Challenges and successes in developing new therapies for hepatitis C Nature 2005, 436, 953-960
13. Malcolm, B. A.; Liu, R.; Lahser, F.; Agrawal, S.; Belanger, B.; Butkiewicz, N.; Chase, R.; Gheyas, F.; Hart, A.; Hesk, D.; Ingravallo, P.; Jiang, C.; Kong, R.; Lu, J.; Pichardo, J.; Prongay, A.; Skelton, A.; Tong, X.; Venkatraman, S.; Xia, E.; Girijavallabhan, V.; Njoroge, F. G. SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells Antimicrob. Agents Chemother. 2006, 50, 1013-1020
14. Perni, R. B.; Almquist, S. J.; Byrn, R. A.; Chandorkar, G.; Chaturvedi, P. R.; Courtney, L. F.; Decker, C. J.; Dinehart, K.; Gates, C. A.; Harbeson, S. L.; Heiser, A.; Kalkeri, G.; Kolaczkowski, E.; Lin, K.; Luong, Y.-P.; Rao, B. G.; Taylor, W. P.; Thomson, J. A.; Tung, R. D.; Wei, Y.; Kwong, A. D.; Lin, C. Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease Antimicrob. Agents Chemother. 2006, 50, 899-909
15. Farnik, H.; Zeuzem, S. New antiviral therapies in the management of HCV infection Antiviral Ther 2012, 17, 771-783
16. Fried, M. W. Side effects of therapy of hepatitis C and their management Hepatology 2002, 36, S237-S244
17. Incivek (telaprevir) in combination with drugs peginterferon alfa and ribavirin (Incivek combination treatment): drug safety communication-serious skin reactions. http://www.fda.gov/Safety/MedWatch/SafetyInformation/ SafetyAlertsforHumanMedicalProducts/ucm332860.htm (posted by the FDA on December 19, 2012.
18. Maasoumy, B.; Manns, M. P. Optimal treatment with boceprevir for chronic HCV infection Liver Int. 2013, 33 (Suppl. 1) 14-22
19. Manns, M. P.; von Hahn, T. Novel therapies for hepatitis C-One pill fits all? Nat. Rev. Drug Discovery 2013, 12, 595-610
20. Ingallinella, P.; Altamura, S.; Bianchi, E.; Taliani, M.; Ingenito, R.; Cortese, R.; De Francesco, R.; Steinkuhler, C.; Pessi, A. Potent peptide inhibitors of human hepatitis C virus NS3 protease are obtained by optimizing the cleavage products Biochemistry 1998, 37, 8906-8914
21. Imperiali, B.; Abeles, R. H. Extended binding inhibitors of chymotrypsin that interact with leaving group subsites S1′-S3′ Biochemistry 1987, 26, 4474-4477
22. Llinas-Brunet, M.; Bailey, M. D.; Cameron, D.; Faucher, A.-M; Ghiro, E.; Goudreau, N.; Halmos, T.; Poupart, M.-A.; Rancourt, J.; Tsantrizos, Y. S.; Wernic, D. M.; Simoneau, B. Preparation of hepatitis C inhibitory tripeptides. World Patent Application WO 2000/0009543, February 24, 2000.
23. Campbell, J. A.; Good, A. World Patent Application WO-2002/060926 A2, August 8, 2002.
24. Schaaf, T. K.; Hess, H.-J. Synthesis and biological activity of carboxyl-terminus modified prostaglandin analogues J. Med. Chem. 1979, 22, 1340-1346
25. Meanwell, N. A. Synopsis of some recent tactical applications of bioisosteres in drug design J. Med. Chem. 2011, 54, 2529-2591
26. Lu, X.; Zhang, H.; Li, X.; Chen, G.; Li, Q.-S.; Luo, Y.; Ruan, B.-F.; Chen, X.-W.; Zhu, H.-L. Design, synthesis and biological evaluation of pyridine acyl sulfonamide derivatives as novel COX-2 inhibitors Bioorg. Med. Chem. 2011, 19, 6827-6832
27. Anilkumar, G. N.; Selyutin, O.; Rosenblum, S. B.; Zeng, Q.; Jiang, Y.; Chan, T.-Y.; Pu, H.; Wang, L.; Bennett, F.; Chen, K. X; Lesburg, C. A.; Duca, J.; Gavalas, S.; Huang, Y.; Pinto, P.; Sannigrahi, M.; Velazquez, F.; Venkatraman, S.; Vibulbhan, B.; Agrawal, S.; Ferrari, E.; Jiang, C.-K.; Huang, H.-C.; Shih, N.-Y.; Njoroge, G. F; Kozlowski, J. A., II. Novel HCV NS5B polymerase inhibitors: discovery of indole C2 acyl sulfonamides Bioorg. Med. Chem. Lett. 2012, 22, 713-717
28. Glunz, P. W.; Zhang, X.; Zou, Y.; Delucca, I.; Nirschl, A. H.; Cheng, X.; Weigelt, C. A.; Cheney, D. L.; Wei, A.; Anumula, R.; Luettgen, J. M.; Rendina, A. R.; Harpel, M.; Luo, G.; Knabb, R.; Wong, P. C.; Wexler, R. R.; Priestley, E. S. Nonbenzamidine acylsulfonamide tissue factor-factor VIIa inhibitors Bioorg. Med. Chem. Lett. 2013, 23, 5244-5248
29. Pietschmann, T.; Bartenschlager, R. The hepatitis C virus replicon system and its application to molecular studies Curr. Opin. Drug Discovery Dev. 2001, 4, 657-664
30. Tsantrizos, Y. S.; Bolger, G.; Bonneau, P.; Cameron, D. R.; Goudreau, N.; Kukolj, G.; LaPlante, S. R.; Llinas-Brunet, M.; Nar, H.; Lamarre, D. Macrocyclic inhibitors of the NS3 protease as potential therapeutic agents of hepatitis C virus infection Angew. Chem., Int. Ed. 2003, 42, 1356-1360
31. Perni, R. B.; Pitlik, J.; Britt, S. D.; Court, J. J.; Courtney, L. F.; Deininger, D. D.; Farmer, L. J.; Gates, C. A.; Harbeson, S. L.; Levin, R. B.; Lin, C.; Lin, K.; Moon, Y.-C.; Luong, Y.-P.; O'Malley, E. T.; Rao, B. G.; Thomson, J. A.; Tung, R. D.; Van Drie, J. H.; Wei, Y. Inhibitors of hepatitis C virus NS3/4A protease 2. Warhead SAR and optimization Bioorg. Med. Chem. Lett. 2004, 14, 1441-1446
32. Johansson, A.; Poliakov, A.; Kerblom, E. A; Wiklund, K.; Lindeberg, G.; Winiwarter, S.; Danielson, U. H.; Samuelsson, B.; Hallberg, A. Acyl sulfonamides as potent protease inhibitors of the hepatitis C virus full-length NS3 (protease-helicase/NTPase): a comparative study of different C-terminals Bioorg. Med. Chem. 2003, 11, 2551-2568
33. Oertqvist, P.; Peterson, S. D.; Aakerblom, E.; Gossas, T.; Sabnis, Y. A.; Fransson, R.; Lindeberg, G.; Danielson, U. H.; Karlen, A.; Sandstroem, A. Phenylglycine as a novel P2 scaffold in hepatitis C virus NS3 protease inhibitors Bioorg. Med. Chem. 2007, 15, 1448-1474
34. Roenn, R.; Gossas, T.; Sabnis, Y. A.; Daoud, H.; Aakerblom, E.; Danielson, U. H.; Sandstroem, A. Evaluation of a diverse set of potential P1 carboxylic acid bioisosteres in hepatitis C virus NS3 protease inhibitors Bioorg. Med. Chem. 2007, 15, 4057-4068
35. Baeck, M.; Johansson, P.-O.; Waangsell, F.; Thorstensson, F.; Kvarnstroem, I.; Ayesa, S.; Waehling, H.; Pelcman, M.; Jansson, K.; Lindstroem, S.; Wallberg, H.; Classon, B.; Rydergård, C.; Vrang, L.; Hamelink, E.; Hallberg, A.; Rosenquist, A.; Samuelsson, B. Novel potent macrocyclic inhibitors of the hepatitis C virus NS3 protease: use of cyclopentane and cyclopentene P2-motifs Bioorg. Med. Chem. 2007, 15, 7184-7202
36. Naud, J.; Lemke, C.; Goudreau, N.; Beaulieu, E.; White, P. D.; Llinas-Brunet, M.; Forgione, P. Potent triazolyl-proline-based inhibitors of HCV NS3 protease Bioorg. Med. Chem. Lett. 2008, 18, 3400-3404
37. Raboisson, P.; de Kock, H.; Rosenquist, A.; Nilsson, M.; Salvador-Oden, L.; Lin, T.-I.; Roue, N.; Ivanov, V.; Wahling, H.; Wickstrom, K.; Hamelink, E.; Edlund, M.; Vrang, L.; Vendeville, S.; Van de Vreken, W.; McGowan, D.; Tahri, A.; Hu, L.; Boutton, C.; Lenz, O.; Delouvroy, F.; Pille, G.; Surleraux, D.; Wigerinck, P.; Samuelsson, B.; Simmen, K. Structure-activity relationship study on a novel series of cyclopentane-containing macrocyclic inhibitors of the hepatitis C virus NS3/4A protease leading to the discovery of TMC435350 Bioorg. Med. Chem. Lett. 2008, 18, 4853-4858
38. Cummings, M. D.; Lindberg, J.; Lin, T.-I.; de Kock, H.; Lenz, O.; Lilja, E.; Fellander, S.; Baraznenok, V.; Nystrom, S.; Nilsson, M.; Vrang, L.; Edlund, M.; Rosenquist, A.; Samuelsson, B.; Raboisson, P.; Simmen, K. Induced-fit binding of the macrocyclic noncovalent inhibitor TMC435 to its HCV NS3/NS4A protease target Angew. Chem., Int. Ed. 2010, 49, 1652-1655
39. Raboisson, P.; Lin, T.-I.; de Kock, H.; Vendeville, S.; Van de Vreken, W.; McGowan, D.; Tahri, A.; Hu, L.; Lenz, O.; Delouvroy, F.; Surleraux, D.; Wigerinck, P.; Nilsson, M.; Rosenquist, A.; Samuelsson, B.; Simmen, K. Discovery of novel potent and selective dipeptide hepatitis C virus NS3/4A serine protease inhibitors Bioorg. Med. Chem. Lett. 2008, 18, 5095-5100
40. Vendeville, S.; Nilsson, M.; de Kock, H.; Lin, T.-I.; Antonov, D.; Classon, B.; Ayesa, S.; Ivanov, V.; Johansson, P.-O.; Kahnberg, P.; Eneroth, A.; Wikstrom, K.; Vrang, L.; Edlund, M.; Lindström, S.; Van de Vreken, W.; McGowan, D.; Tahri, A.; Hu, L.; Lenz, O.; Delouvroy, F.; Van Dooren, M.; Kindermans, N.; Surleraux, D.; Wigerinck, P.; Rosenquist, A.; Samuelsson, B.; Simmen, K.; Raboisson, P. Discovery of novel, potent and bioavailable proline-urea based macrocyclic HCV NS3/4A protease inhibitors Bioorg. Med. Chem. Lett. 2008, 18, 6189-6193
41. Nilsson, M.; Belfrage, A. K.; Lindstroem, S.; Waehling, H.; Lindquist, C.; Ayesa, S.; Kahnberg, P.; Pelcman, M.; Benkestock, K.; Agback, T.; Vrang, L.; Terelius, Y.; Wikström, K.; Hamelink, E.; RydergaÌŠrd, C.; Edlund, M.; Eneroth, A.; Raboisson, P.; Lin, T.-I.; de Kock, H.; Wigerinck, P.; Simmen, K.; Samuelsson, B.; Rosenquist, A. Synthesis and SAR of potent inhibitors of the hepatitis C virus NS3/4A protease: exploration of P2 quinazoline substituents Bioorg. Med. Chem. Lett. 2010, 20, 4004-4011
42. Lampa, A.; Ehrenberg, A. E.; Gustafsson, S. S.; Vema, A.; Aakerblom, E.; Lindeberg, G.; Karlen, A.; Danielson, U. H.; Sandstroem, A. Improved P2 phenylglycine-based hepatitis C virus NS3 protease inhibitors with alkenylic prime-side substituents Bioorg. Med. Chem. 2010, 18, 5413-5424
43. Oertqvist, P.; Gising, J.; Ehrenberg, A. E.; Vema, A.; Borg, A.; Karlen, A.; Larhed, M.; Danielson, U. H; Sandstroem, A. Discovery of achiral inhibitors of the hepatitis C virus NS3 protease based on 2(1 H)-pyrazinones Bioorg. Med. Chem. 2010, 18, 6512-6525
44. Oertqvist, P.; Vema, A.; Ehrenberg, A. E.; Dahl, G.; Roenn, R.; Aekerblom, E.; Karlen, A.; Danielson, U. H.; Sandstroem, A. Structure-activity relationships of HCV NS3 protease inhibitors evaluated on the drug-resistant variants A156T and D168V Antiviral Ther. 2010, 15, 841-852
45. Ding, C. Z.; Zhang, Y.-K.; Li, X.; Liu, Y.; Zhang, S.; Zhou, Y.; Plattner, J. J.; Baker, S. J.; Liu, L.; Duan, M.; Jarvest, R. L.; Ji, J.; Kazmierski, W. M.; Tallant, M. D.; Wright, L. L.; Smith, G. K.; Crosby, R. M.; Wang, A. A.; Ni, Z.-J.; Zoue, W.; Wright, J. Synthesis and biological evaluations of P4-benzoxaborole-substituted macrocyclic inhibitors of HCV NS3 protease Bioorg. Med. Chem. Lett. 2010, 20, 7317-7322
46. Duan, M.; Kazmierski, W.; Crosby, R.; Gartland, M.; Ji, J.; Tallant, M.; Wang, A.; Hamatake, R.; Wright, L.; Wu, M.; Zhang, Y.-K.; Ding, C. Z.; Li, X.; Liu, Y.; Zhang, S.; Zhou, Y.; Plattner, J. J.; Baker, S. J. Discovery of novel P3-oxo inhibitor of hepatitis C virus NS3/4A serine protease Bioorg. Med. Chem. Lett. 2012, 22, 2993-2996
47. Kazmierski, W. M.; Hamatake, R.; Duan, M.; Wright, L. L.; Smith, G. K.; Jarvest, R. L.; Ji, J.-J.; Cooper, J. P.; Tallant, M. D.; Crosby, R. M.; Creech, K.; Wang, A.; Li, X.; Zhang, S.; Zhang, Y.-Y.; Liu, Y.; Ding, C. Z.; Zhou, Y.; Plattner, J. J.; Baker, S. J.; Bu, W.; Liu, L. Discovery of novel urea-based hepatitis C protease inhibitors with high potency against protease-inhibitor- resistant mutants J. Med. Chem. 2012, 55, 3021-3026
48. McCauley, J. A.; McIntyre, C. J.; Rudd, M. T.; Nguyen, K. T.; Romano, J. J.; Butcher, J. W.; Gilbert, K. F.; Bush, K. J.; Holloway, M. K.; Swestock, J.; Wan, B.-L.; Carroll, S. S.; DiMuzio, J. M.; Graham, D. J.; Ludmerer, S. W.; Mao, S.-S.; Stahlhut, M. W.; Fandozzi, C. M.; Trainor, N.; Olsen, D. B.; Vacca, J. P.; Liverton, N. J. Discovery of vaniprevir (MK-7009), a macrocyclic hepatitis C virus NS3/4a protease inhibitor J. Med. Chem. 2010, 53, 2443-2463
49. Liverton, N. J.; Holloway, M. K.; McCauley, J. A.; Rudd, M. T.; Butcher, J. W.; Carroll, S. S.; DiMuzio, J.; Fandozzi, C.; Gilbert, K. F.; Mao, S.-S.; McIntyre, C. J.; Nguyen, K. T.; Romano, J. J.; Stahlhut, M.; Wan, B.-L.; Olsen, D. B.; Vacca, J. P. Molecular modeling based approach to potent P2-P4 macrocyclic inhibitors of hepatitis C NS3/4A protease J. Am. Chem. Soc. 2008, 130, 4607-4609
50. McCauley, J. A.; Rudd, M. T.; Nguyen, K. T.; McIntyre, C. J.; Romano, J. J.; Bush, K. J.; Varga, S. L.; Ross, C. W., III; Carroll, S. S.; DiMuzio, J.; Stahlhut, M. W.; Olsen, D. B.; Lyle, T. A.; Vacca, J. P.; Liverton, N. J. Bismacrocyclic inhibitors of hepatitis C NS3/4a protease Angew. Chem., Int. Ed. 2008, 47, 9104-9107
51. Harper, S.; Ferrara, M.; Crescenzi, B.; Pompei, M.; Palumbi, M. C.; Di Muzio, J. M.; Donghi, M.; Fiore, F.; Koch, U.; Liverton, N. J.; Pesci, S.; Petrocchi, A.; Rowley, M.; Summa, V.; Gardelli, C. Inhibitors of the hepatitis C virus NS3 protease with basic amine functionality at the P3-amino acid N-terminus: discovery and optimization of a new series of P2-P4 macrocycles J. Med. Chem. 2009, 52, 4820-4837
52. Di Francesco, M. E.; Dessole, G.; Nizi, E.; Pace, P.; Koch, U.; Fiore, F.; Pesci, S.; Di Muzio, J.; Monteagudo, E.; Rowley, M.; Summa, V. Novel macrocyclic inhibitors of hepatitis C NS3/4A protease featuring a 2-amino-1,3-thiazole as a P4 carbamate replacement J. Med. Chem. 2009, 52, 7014-7028
53. Rudd, M. T.; McCauley, J. A.; Butcher, J. W.; Romano, J. J.; McIntyre, C. J.; Nguyen, K. T.; Gilbert, K. F.; Bush, K. J.; Holloway, M. K.; Swestock, J.; Wan, B.-L.; Carroll, S. S.; DiMuzio, J. M.; Graham, D. J.; Ludmerer, S. W.; Stahlhut, M. W.; Fandozzi, C. M.; Trainor, N.; Olsen, D. B.; Vacca, J. P.; Liverton, N. J. Discovery of MK-1220: a macrocyclic inhibitor of hepatitis C virus NS3/4A protease with improved preclinical plasma exposure ACS Med. Chem. Lett. 2011, 2, 207-212
54. Harper, S.; McCauley, J. A.; Rudd, M. T.; Ferrara, M.; DiFilippo, M.; Crescenzi, B.; Koch, U.; Petrocchi, A.; Holloway, M. K.; Butcher, J. W.; Romano, J. J.; Bush, K. J.; Gilbert, K. F.; McIntyre, C. J.; Nguyen, K. T.; Nizi, E.; Carroll, S. S.; Ludmerer, S. W.; Burlein, C.; DiMuzio, J. M.; Graham, D. J.; McHale, C. M.; Stahlhut, M. W.; Olsen, D. B.; Monteagudo, E.; Cianetti, S.; Giuliano, C.; Pucci, V.; Trainor, N.; Fandozzi, C. M.; Rowley, M.; Coleman, P. J.; Vacca, J. P.; Summa, V.; Liverton, N. J. Discovery of MK-5172, a macrocyclic hepatitis C virus NS3/4a protease inhibitor ACS Med. Chem. Lett. 2012, 3, 332-336
55. Rudd, M. T.; McCauley, J. A.; Romano, J. J.; Butcher, J. W.; Bush, K.; McIntyre, C. J.; Nguyen, K. T.; Gilbert, K. F.; Lyle, T. A.; Holloway, M. K; Wan, B.-L.; Vacca, J. P.; Summa, V.; Harper, S.; Rowley, M.; Carroll, S. S.; Burlein, C.; DiMuzio, J. M.; Gates, A.; Graham, D. J.; Huang, Q.; Ludmerer, S. W.; McClain, S.; McHale, C.; Stahlhut, M.; Fandozzi, C.; Taylor, A.; Trainor, N.; Olsen, D. B.; Liverton, N. J. Development of potent macrocyclic inhibitors of genotype 3a HCV NS3/4A protease Bioorg. Med. Chem. Lett. 2012, 22, 7201-7206
56. Rudd, M. T.; McIntyre, C. J.; Romano, J. J.; Butcher, J. W.; Holloway, M. K.; Bush, K.; Nguyen, K. T.; Gilbert, K. F.; Lyle, T. A.; Liverton, N. J.; Wan, B.-L; Summa, V.; Harper, S.; Rowley, M.; Vacca, J. P.; Carroll, S. S.; Burlein, C.; DiMuzio, J. M.; Gates, A.; Graham, D. J.; Huang, Q.; Ludmerer, S. W.; McClain, S.; McHale, C.; Stahlhut, M.; Fandozzi, C.; Taylor, A.; Trainor, N.; Olsen, D. B.; McCauley, J. A. Development of macrocyclic inhibitors of HCV NS3/4A protease with cyclic constrained P2-P4 linkers Bioorg. Med. Chem. Lett. 2012, 22, 7207-7213
57. Li, X.; Liu, Y.; Zhang, Y.-K.; Plattner, J. J.; Baker, S. J.; Bu, W.; Liu, L.; Zhou, Y.; Ding, C. Z.; Zhang, S.; Kazmierski, W. M.; Hamatake, R.; Duan, M.; Wright, L. L.; Smith, G. K.; Jarvest, R. L.; Ji, J.-J.; Cooper, J. P.; Tallant, M. D.; Crosby, R. M.; Creech, K.; Wang, A. Synthesis and antiviral activity of novel HCV NS3 protease inhibitors with P4 capping groups Bioorg. Med. Chem. Lett. 2012, 22, 7351-7356
58. Bilodeau, F.; Bailey, M. D.; Bhardwaj, P. K.; Bordeleau, J.; Forgione, P.; Garneau, M.; Ghiro, E.; Gorys, V.; Halmos, T.; Jolicoeur, E. S.; Leblanc, M.; Lemke, C. T.; Naud, J.; O'Meara, J.; White, P. W.; Llinàs-Brunet, M. Synthesis and optimization of a novel series of HCV NS3 protease inhibitors: 4-arylproline analogs Bioorg. Med. Chem. Lett. 2013, 23, 4267-4271
59. Bailey, M. D.; Halmos, T.; Lemke, C. T. Discovery of novel P2 substituted 4-biaryl proline inhibitors of hepatitis C virus NS3 serine protease Bioorg. Med. Chem. Lett. 2013, 23, 4436-4440
60. Bailey, M. D.; Bordeleau, J.; Garneau, M.; Leblanc, M.; Lemke, C. T.; O'Meara, J.; White, P. W.; Llinas-Brunet, M. Peptide backbone replacement of hepatitis C virus NS3 serine protease C-terminal cleavage product analogs: discovery of potent succinamide inhibitors Bioorg. Med. Chem. Lett. 2013, 23, 4447-4452
61. Moreau, B.; O'Meara, J. A.; Bordeleau, J.; Garneau, M.; Godbout, C.; Gorys, V.; Leblanc, M.; Villemure, E.; White, P. W.; Llinas-Brunet, M. Discovery of hepatitis C Virus NS3-4A protease inhibitors with improved barrier to resistance and favorable liver distribution. J. Med. Chem. 2013, DOI: 10.1021/jm400121t.
62. Seiwert, S. D.; Andrews, S. W.; Jiang, Y.; Serebryany, V.; Tan, H.; Kossen, K.; Rajagopalan, P. T. R.; Misialek, S.; Stevens, S. K.; Stoycheva, A.; Hong, J.; Lim, S. R.; Qin, X.; Rieger, R.; Condroski, K. R.; Zhang, H.; Do, M. G.; Lemieux, C.; Hingorani, G. P.; Hartley, D. P.; Josey, J. A.; Pan, L.; Beigelman, L.; Blatt, L. M. Preclinical characteristics of the hepatitis C virus NS3/4A protease inhibitor ITMN-191 (R7227) Antimicrob. Agents Chemother. 2008, 52, 4432-4441
63. Jiang, Y.; Andrews, S. W.; Condroski, K. R.; Buckman, B.; Serebryany, V.; Wenglowsky, S.; Kennedy, A. L.; Madduru, M. R.; Wang, B.; Lyon, M.; Doherty, G. A.; Woodard, B. T.; Lemieux, C.; Geck Do, M.; Zhang, H.; Ballard, J.; Vigers, G.; Brandhuber, B. J.; Stengel, P.; Josey, J. A.; Beigelman, L.; Blatt, L.; Seiwert, S. D. Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent Inhibitor of hepatitis C virus (HCV) NS3/4A protease J. Med. Chem. 2014, 10.1021/jm400164c
64. Vispo, E.; Barreiro, P.; Soriano, V. Pharmacokinetics of new oral hepatitis C antiviral drugs Expert Opin. Drug Metab. Toxicol. 2013, 9, 5-16
65. Reddy, M. B.; Morcos, P. N.; Le Pogam, S.; Ou, Y.; Frank, K.; Lave, T.; Smith, P. Pharmacokinetic/pharmacodynamic predictors of clinical potency for hepatitis C virus nonnucleoside polymerase and protease inhibitors Antimicrob. Agents Chemother. 2012, 56, 3144-3156
66. Lindenbach, B. D.; Rice, C. M. Unravelling hepatitis C virus replication from genome to function Nature 2005, 436, 933-938
67. Meanwell, N. A. Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety Chem. Res. Toxicol. 2011, 24, 1420-1456
68. Llinàs-Brunet, M.; Bailey, M. D.; Ghiro, E.; Gorys, V.; Halmos, T.; Poirier, M.; Rancourt, J.; Goudreau, N. A systematic approach to the optimization of substrate-based inhibitors of the hepatitis C virus NS3 protease: discovery of potent and specific tripeptide inhibitors J. Med. Chem. 2004, 47 (26) 6584-6594
69. Johnson, F. Allylic strain in six-membered rings Chem. Rev. 1968, 68, 375-413
70. Anderson, G. M., III; Kollman, P. A.; Domelsmith, L. N.; Houk, K. N. Methoxy group nonplanarity in o -dimethoxybenzenes. Simple predictive models for conformations and rotational barriers in alkoxyaromatics J. Am. Chem. Soc. 1979, 101, 2344-2352
71. Mecozzi, S.; West, A. P.; Doughtery, D. A. Cation-pi interactions in aromatics of biological and medicinal interest: electrostatic potential surfaces as a useful qualitative guide Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 10566-10571
72. Hansch, C.; Leo, A.; Unger, S. H.; Kim, K. H.; Nikaitani, D.; Lien, E. J. Aromatic substituent constants for structure-activity correlations J. Med. Chem. 1973, 16, 1207-1216
73. Dougherty, D. A. The cation-π interaction Acc. Chem. Res. 2013, 46, 885-893
74. Fleming, F. F.; Yao, L.; Ravikumar, P. C.; Funk, L.; Shook, B. C. Nitrile-containing pharmaceuticals: efficacious roles of the nitrile pharmacophore J. Med. Chem. 2010, 53 (22) 7902-17
75. Wheeler, S. E. Understanding substituent effects in noncovalent interactions involving aromatic rings Acc. Chem. Res. 2013, 46, 1029-1038
76. Yedidi, R. S.; Maeda, K.; Fyvie, W. S.; Steffey, M.; Davis, D. A.; Palmer, I.; Aoki, M.; Kaufman, J. D.; Stahl, S. J.; Garimella, H.; Das, D.; Wingfield, P. T.; Ghosh, A. K.; Mitsuya, H. P2′ benzene carboxylic acid moiety is associated with decrease in cellular uptake: evaluation of novel nonpeptidic HIV-1 protease inhibitors containing P2 bis-tetrahydrofuran moiety Antimicrob. Agents Chemother. 2013, 57 (10) 4920-4927
77. Han, Y.; Busler, D.; Hong, Y.; Tian, Y.; Cliff Chen, C.; Rodrigues, D. A. Transporter studies with the 3- O -sulfate conjugate of 17α- ethinylestradiol: human liver drug transporters Drug Metab. Dispos. 2010, 38 (7) 1072-82
78. Wang, Z. A.; Sun, L.-Q.; Sit, S.-Y.; Sin, N.; Scola, P. M.; Hewawasam, P.; Good, A. C.; Chen, Y.; Campbell, J. A. Preparation of peptides as hepatitis C virus inhibitors. World Patent Application WO-2003/099274 A1, December 4, 2003.
79. Briet, N.; Brookes, M. H.; Davenport, R. J.; Galvin, F. C. A.; Gilbert, P. J.; Mack, S. R.; Sabin, V. Synthesis of novel substituted isoquinolones Tetrahedron 2002, 58, 5761-5766
80. Llinas-Brunet, M.; Bailey, M.; Fazal, G.; Ghiro, E.; Gorys, V.; Goulet, S.; Halmos, T.; Maurice, R.; Poirier, M.; Poupart, M.-A.; Rancourt, J.; Thibeault, D.; Wernic, D.; Lamarre, D. Highly potent and selective peptide-based inhibitors of the hepatitis C virus serine protease: towards smaller inhibitors Bioorg. Med. Chem. Lett. 2000, 10, 2267-2270
81. Li, J.; Smith, D.; Wong, H. S.; Campbell, J. A.; Meanwell, N. A.; Scola, P. M. A facile synthesis of 1-substituted cyclopropylsulfonamides Synlett 2006, 725-728
82. McPhee, F.; Sheaffer, A. K.; Friborg, J.; Hernandez, D.; Falk, P.; Zhai, G.; Levine, S.; Chaniewski, S.; Yu, F.; Barry, D.; Chen, C.; Lee, M. S.; Mosure, K.; Sun, L.-Q.; Sinz, M.; Meanwell, N. A.; Colonno, R. J.; Knipe, J.; Scola, P. Preclinical profile and characterization of the hepatitis C virus NS3 protease inhibitor asunaprevir (BMS-650032) Antimicrob. Agents Chemother. 2012, 56, 5387-5396
83. Lok, A. S.; Gardiner, D. F.; Lawitz, E.; Martorell, C.; Everson, G. T.; Ghalib, R.; Reindollar, R.; Rustgi, V.; McPhee, F.; Wind-Rotolo, M.; Persson, A.; Zhu, K.; Dimitrova, D. I.; Eley, T.; Guo, T.; Grasela, D. M.; Pasquinelli, C. Preliminary study of two antiviral agents for hepatitis C genotype 1 N. Engl. J. Med. 2012, 366, 216-224